Premium
Albumin‐binding MR blood pool agents as MRI contrast agents in an intracranial mouse glioma model
Author(s) -
Adzamli Kofi,
Yablonskiy Dmitriy A.,
Chicoine Michael R.,
Won Eun Kyung,
Galen Karen P.,
Zahner Michael C.,
Woolsey Thomas A.,
Ackerman Joseph J.H.
Publication year - 2003
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/mrm.10382
Subject(s) - contrast (vision) , glioma , albumin , magnetic resonance imaging , central nervous system , contrast enhancement , medicine , extracellular , nuclear medicine , chemistry , pathology , radiology , cancer research , biochemistry , artificial intelligence , computer science
Intravenous MRI contrast agents are commonly used to improve the detection of intracranial tumors and other central nervous system (CNS) lesions for diagnosis and treatment planning. Two small‐molecule, albumin‐binding blood pool contrast agents (MP‐2269 and MS‐325) of potential clinical significance were evaluated at 1.5 Tesla in a mouse glioma model and compared with an extracellular contrast agent (OptiMARK). Tumor image contrast was significantly enhanced and long‐lived following administration of 30 μmole/kg of the blood pool agents: specifically, contrast enhancement peaked slowly at 25–30 min following administration, remained constant for >3 hr, and returned to baseline within 20 hr. Comparable but “transient” enhancement was achieved using 100 μmole/kg OptiMARK: specifically, contrast enhancement peaked rapidly at 2–5 min following administration and then declined over 40 min. The blood pool contrast agents demonstrated an approximately threefold increased dose‐effectiveness and a lengthened window of tumor contrast enhancement in comparison to commonly available extracellular contrast agents. This demonstrates the potential of alternative contrast‐enhanced (CE) MRI examination protocols for tumor detection. Magn Reson Med 49:586–590, 2003. © 2003 Wiley‐Liss, Inc.